Pelareorep is currently being manufactured at commercial scale in its final formulation under a commercial supply agreement with MilliporeSigma (formerly Sigma-Aldrich), the life science business of Merck KGaA. Under the current terms of the agreement, MilliporeSigma will manufacture all necessary product for clinical testing, as well as commercial product subject to the receipt of regulatory approval.

As of January 2022, Oncolytics has enough product on hand and in scheduled production to supply all ongoing and upcoming studies as well as the proposed phase 3 registration study in metastatic breast cancer.